

HELP ENSURE YOUR PATIENTS RECEIVE THE VALTOCO YOU'VE PRESCRIBED

**VALTOCO is currently available for order
through Maxor Specialty Pharmacy**

**Please see Important Safety Information, including Boxed Warning,
on the back.**



MAXOR SPECIALTY PHARMACY OFFERS:

- ◆ Access to VALTOCO copay assistance program*
- ◆ Insurance claim and prior authorization processing
- ◆ Guaranteed product availability
- ◆ 24/7 access to a pharmacist
- ◆ Customized refill reminders
- ◆ Convenient home delivery



Provide the prescription and Maxor Specialty Pharmacy will take care of the rest.

TO PRESCRIBE VALTOCO FOLLOW THESE STEPS:

1. **Submit VALTOCO prescription to Maxor Specialty Pharmacy.**
Please be sure to include dosage, number of boxes, and amount of refills.
 Send VALTOCO prescription via fax to Maxor Specialty Pharmacy:
 1-866-217-8034
 OR
 E-prescribe to:
 Maxor Specialty Pharmacy
 216 S Polk, Amarillo, TX 79101
 Ph: 1-866-629-6779
 NCPDPID: 5905661
 If you are having trouble finding "Maxor Specialty Pharmacy" in the system, you may locate using the pharmacy phone (1-866-629-6779) or ZIP code (79101).
2. **Bookmark "Maxor Specialty Pharmacy"** as a favorite in your e-prescribing system for future use.
3. **Ensure all required patient information is included** to avoid delays in processing the prescription. Don't forget to include: patient first name, last name, DOB, gender, and pharmacy benefit information: BIN, PCN, Group ID#.
4. A Maxor representative will contact you within 24 hours if prior authorization or clarification is needed.

*Subject to eligibility. For private insurance programs only.

THE FOLLOWING TIPS CAN HELP WITH THE PROCESS



PRIOR AUTHORIZATIONS

Some insurance plans may require prior authorization to cover a patient's prescription. Maxor Specialty Pharmacy will initiate the authorization process and work with the insurer, physician/office staff, and the patient until the authorization process is completed.



TALK TO YOUR PATIENTS ABOUT THE MAXOR SPECIALTY PHARMACY ORDERING PROCESS

After you have requested VALTOCO through Maxor Specialty Pharmacy, it is important you communicate this information to your patients.



HELP ENSURE THEY CONFIRM THEIR ORDER

24 hours after order confirmation, a Maxor Specialty Pharmacy representative will call the patient to confirm their order. This call will come from 1-866-629-6779. Let your patients know they MUST respond to the call to process the order.



REMIND THEM THEIR INSURANCE STILL NEEDS TO BE PROCESSED

If applicable, Maxor Specialty Pharmacy will call your patients to communicate the final copay of their medication after they have processed their insurance claim. They will then process the transaction.



LET THEM KNOW VALTOCO WILL BE DELIVERED TO THEIR HOME

Remind your patients that Maxor Specialty Pharmacy provides free shipping of their medication. Order will be sent through UPS or FedEx and will require an adult signature upon delivery of VALTOCO.

FOR MORE INFORMATION:

Visit **www.MaxorSpecialty.com** or call 1-866-629-6779 Monday-Friday, 8 AM to 5 PM CT

Indication

VALTOCO® (diazepam nasal spray) is indicated for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity (ie, seizure clusters, acute repetitive seizures) that are distinct from a patient's usual seizure pattern in patients with epilepsy 6 years of age and older.



IMPORTANT SAFETY INFORMATION

RISK FROM CONCOMITANT USE WITH OPIOIDS

Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death.

- **Reserve concomitant prescribing of these drugs for use in patients for whom alternative treatment options are inadequate**
- **Limit dosages and durations to the minimum required**
- **Follow patients for signs and symptoms of respiratory depression and sedation**

Contraindications: VALTOCO is contraindicated in patients with:

- Known hypersensitivity to diazepam
- Acute narrow-angle glaucoma

Central Nervous System (CNS) Depression

Benzodiazepines, including VALTOCO, may produce CNS depression. Caution patients against engaging in hazardous activities requiring mental alertness, such as operating machinery, driving a motor vehicle, or riding a bicycle, until the effects of the drug, such as drowsiness, have subsided, and as their medical condition permits.

The potential for a synergistic CNS-depressant effect when VALTOCO is used with alcohol or other CNS depressants must be considered, and appropriate recommendations made to the patient and/or care partner.

Suicidal Behavior and Ideation

Antiepileptic drugs (AEDs), including VALTOCO, increase the risk of suicidal ideation and behavior. Patients treated with any AED for any indication should be monitored for the emergence or worsening of depression, suicidal thoughts or behavior, and/or unusual changes in mood or behavior. Advise patients and caregivers to be alert for these behavioral changes and to immediately report them to a healthcare provider.

Glaucoma

Benzodiazepines, including VALTOCO, can increase intraocular pressure in patients with glaucoma. VALTOCO may only be used in patients with open-angle glaucoma only if they are receiving appropriate therapy. VALTOCO is contraindicated in patients with narrow-angle glaucoma.

Risk of Serious Adverse Reactions in Infants due to Benzyl Alcohol Preservative

VALTOCO is not approved for use in neonates or infants. Serious and fatal adverse reactions, including "gasping syndrome," can occur in neonates and low-birth-weight infants treated with benzyl alcohol-preserved drugs, including VALTOCO. The "gasping syndrome" is characterized by central nervous system depression, metabolic acidosis, and gasping respirations. The minimum amount of benzyl alcohol at which serious adverse reactions may occur is not known.

Adverse Reactions

The most common adverse reactions (at least 4%) were somnolence, headache, and nasal discomfort.

Diazepam, the active ingredient in VALTOCO, is a Schedule IV controlled substance.

To report SUSPECTED ADVERSE REACTIONS, contact Neurelis, Inc. at 1-866-696-3873 or FDA at 1-800-FDA-1088 (www.fda.gov/medwatch).

Please read full Prescribing Information, including Boxed Warning, located in pocket for additional important safety information.

NEURELIS, VALTOCO, and the NEURELIS and VALTOCO logos are registered trademarks of Neurelis, Inc.

All other trademarks are the property of their respective owners.

© Neurelis, Inc. 2020. All rights reserved.

US-PRC-20-00235

